3. Approximate Dose Equivalency of Statin LDL-C Efficacy

4. Residual CV Risk

5. Approaches to Reducing Residual Risk

6. IMPROVE-IT Efficacy

7. IMPROVE-IT Safety

9. ODYSSEY Long-Term Time to First Adjudicated Major CV Event

10. Safety of Intensive LDL-C Lowering

11. ODYSSEY HIGH FH

12. ODYSSEY ALTERNATIVE: PCSK9 in Statin-Intolerant Patients Study Design

13. Alirocumab Significantly Reduced LDL-C in Statin-Intolerant Patients

14. Incidence of Muscle AEs on Statin Therapy

15. LDL-C Lowering Cognitive Impairment

17. Combination Therapy

18. PCSK9 Mutations

19. Abbreviations

20. Abbreviations (cont)

21. Abbreviations (cont)

22. Abbreviations (cont)

23. References

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)